Amgen Presents Early-Stage Clinical Trial Data at ESMO 2024, Showcasing Oncology Pipeline
核心洞察
Amgen is presenting data from early-stage trials at ESMO 2024, highlighting targeted therapies for various cancers, including colorectal, lung, prostate, and gastric, showcasing the breadth of their oncology pipeline.
The CodeBreaK 101 study reveals initial findings of LUMAKRAS combined with Vectibix and FOLFIRI as a first-line treatment for KRAS (搜索) G12C-mutated metastatic colorectal cancer (搜索).
First-in-human study results of xaluritamig in metastatic castration-resistant prostate cancer (搜索) are being presented, alongside Phase 1 data for AMG 193 in MTAP (搜索)-deleted solid tumors.
Amgen (NASDAQ: AMGN) is presenting new data from its oncology pipeline at the European Society for Medical Oncology (ESMO) Congress 2024, held in Barcelona from September 13-17. The data includes Amgen-sponsored and investigator-sponsored studies focusing on molecularly targeted modalities for colorectal, lung, prostate, and gastric cancers.
Jay Bradner, M.D., Executive Vice President, Research and Development, and Chief Scientific Officer at Amgen, stated, "The breadth of these data reflects our strategy to advance diverse modalities for difficult-to-treat cancers. These ESMO results underscore our leadership in oncology, contributing significant advancements with both investigational and established therapies. Guided by a deep understanding of cancer biology and leveraging incisive therapeutics, we can target dominant drivers of disease with unprecedented precision."
Combination Therapy for Metastatic Colorectal Cancer
First findings from the Phase 1b CodeBreaK 101 study of LUMAKRAS® (sotorasib) plus Vectibix® (panitumumab) in combination with FOLFIRI in first-line patients with KRAS (搜索) G12C-mutated metastatic colorectal cancer (搜索) (mCRC) are being presented. Colorectal cancer (CRC) is the second leading cause of cancer deaths worldwide, accounting for 10% of all cancer diagnoses. KRAS mutations are common in colorectal cancers, with the KRAS G12C mutation present in approximately 3-5% of cases.
Novel PRMT5 Inhibitor for MTAP-Deleted Solid Tumors
Phase 1 dose escalation and initial dose expansion data from AMG 193, an MTA-cooperative PRMT5 inhibitor, were selected for a presidential symposium session. This study focuses on patients with MTAP (搜索)-deleted solid tumors, representing a targeted approach to cancers with specific genetic deletions.
First-in-Human Study of Xaluritamig in Prostate Cancer
The first-in-human study of xaluritamig in men with metastatic castration-resistant prostate cancer (搜索) (mCRPC) is being presented. This research explores a novel therapeutic approach for prostate cancer, which remains a significant cause of mortality in men worldwide.
Sotorasib Clinical Outcomes in NSCLC
Long-term clinical outcomes of sotorasib in pre-treated KRAS (搜索) G12C-mutated advanced non-small cell lung cancer (搜索) (NSCLC) are being presented as a pooled analysis from the CodeBreaK clinical trials. Lung cancer is the leading cause of cancer-related deaths globally, with KRAS G12C being the most common KRAS mutation in NSCLC, found in about 13% of non-squamous NSCLC patients.
Biomarker Analysis in Gastric Cancer
Data on fibroblast growth factor receptor 2 isoform IIIb (FGFR2b (搜索)) protein overexpression and biomarker overlap in patients with advanced gastric or gastroesophageal junction cancer (GC/GEJC) for bemarituzumab are being presented. Gastric cancer (搜索) remains a significant global health challenge, and identifying predictive biomarkers is crucial for targeted therapies.
Investigator-Sponsored Studies on Vectibix
Several investigator-sponsored studies on Vectibix (panitumumab) are also part of the presentations, including mRNA profiling as a biomarker of prognosis and response to first-line treatment in metastatic colorectal cancer (搜索) and circulating tumor DNA driving anti-EGFR (搜索) rechallenge therapy in metastatic colorectal cancer.